Cosmos Holdings to Acquire LIFE NLB Portfolio of Bone Health Products Targeting the Gastrointestinal Microbiome

Acquisition will include all bone health products launched and in development

CHICAGO, IL/ACCESSWIRE/July 6, 2022/ Cosmos Holdings, Inc. (“the company”) (Nasdaq: COSM), an international pharmaceutical company with an exclusive line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, over-the-counter drugs and medical devices, announced today that it has entered into an agreement to acquire the portfolio of LIFE NLB, Ltd. products, including Bone-Vio® and Bone-X, related to bone health targeting the human gastrointestinal microbiome.

The gut microbiome has been proposed as a new therapeutic target for osteoporosis. It is thought to contribute to the integrity of the intestinal barrier and mineral absorption, which is strongly correlated with bone mass. Changes in the gut microbiome have been shown to lead to changes in the expression of cytokines and growth factors that affect the immune, endocrine, vascular and nervous systems, which in turn affect the regulation of differentiation and/or the functioning of bone cells. LIFE NLB’s Bone-Vio® product is a combination of calcium citrate, vitamin D and prebiotics that target the microbiome. Bone-Vio® is currently being evaluated in a clinical trial with results expected to be published in 2023.

Cosmos Holdings, Inc., Wednesday, July 6, 2022, press release photo

According to ReportLinker, the global Osteoporosis Drugs Market was valued at USD 13.36 Billion in 2020 and is expected to grow at a CAGR of 6.83% to reach USD 20.17 Billion by 2026. prevalence of osteoporosis among postmenopausal women and increasing public awareness about osteoporosis care are key factors propelling the growth of the market. Additionally, increasing investments in R&D activities for the development of advanced new drug classes and a broad portfolio of drugs being approved for clinical trials are expected to provide significant growth opportunities for anti-inflammatory drug manufacturers. osteoporosis.

Nikos Bardakis, Founder of LIFE NLB, said, “A key issue with most bone health products on the market is inadequate absorption and bioavailability, as the ingredients often do not effectively cross the intestinal barrier and present usually a low plasma concentration. We have designed our bone health products to ensure adequate absorption, maximizing the benefits of the ingredients contained. We look forward to working with Cosmos to continue research and develop innovative new products targeting bone health.

Greg Siokas, CEO of Cosmos Holdings, said, “This acquisition allows us to enter the growing osteoporosis drug market with potentially superior products that uniquely target the gut microbiome for skeletal health. This is a strategic step, following the R&D partnership with Cloudpharm, towards building a competitive portfolio targeting the gut microbiota, which is vital in many diseases involving bone loss. Probiotics, prebiotics and dietary supplements have been suggested to protect bone health by altering the composition of the gut microbiota. LIFE NLB’s product portfolio contains unique formulations of prebiotics, which are believed to lead to improved absorption and bioavailability. We are delighted to leverage the products of LIFE NLB through our established global distribution network.

About Life NLB, Ltd.

LIFE NLB Ltd. develops, imports and distributes unique nutritional supplements and medical devices operating in Greece. It was founded in 2016 and has developed partnerships with European companies such as Enzymatica, Eubage, Bitop AG and local Greek companies such as Theracell, Cloudpharm, Cana Laboratories in addition to academic institutions such as the Hellenic National Research Foundation, the Athens Medical School LMRS, and the University of Western Attica.

About Cosmos Holdings, Inc.

Cosmos Holdings Inc. (Nasdaq:COSM) is an international pharmaceutical company, with a proprietary line of nutraceuticals and a distributor of branded and generic pharmaceuticals, nutraceuticals, over-the-counter drugs and medical devices through a extensive distribution network established in the EU. The Company identifies, acquires, develops and markets products that improve the lives and outcomes of patients. Cosmos has developed a global distribution platform and is currently expanding across Europe, Asia and North America. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece, Athens, Greece and Harlow, UK. More information is available at www.cosmosholdingsinc.com and www.skypremiumlife.com.

Forward-looking statements

Except for historical information contained in this press release, matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act. of 1934. , as amended. Statements preceded, followed or otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “projects”, “estimates”, “plans” and similar expressions or future or conditional verbs such as “shall”, “should”, “should”, “may” and “could”, are generally forward-looking in nature and not historical fact, although not all forward-looking statements include this who is before. These statements involve unknown risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons beyond the Company’s control, including, but not limited to, the Company’s ability to raise sufficient funding to implement its business plans, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company’s business, operations and economy generally, and the ability to the Company to successfully develop and market its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available on the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact with Investor Relations:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: COSM@crescendo-ir.com

THE SOURCE: Cosmos Holdings, Inc.

See the source version on accesswire.com:
https://www.accesswire.com/707689/Cosmos-Holdings-to-Acquire-LIFE-NLB-Portfolio-of-Bone-Health-Products-that-Target-the-Gastrointestinal-Microbiome


Source link

Comments are closed.